Work

Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.4_suppl.363

Authors: Claire Mulvey, Nitya Prabhakar Raj, Jennifer A. Chan, Rahul Raj Aggarwal, Pelin Cinar, Thomas A Hope, Kanti Kolli, Li Zhang, Susan Calabrese, Jennifer Ann Grabowsky, Lila Modarresi, Virginia Kelly, Danielle Stonely, Pamela N. Munster, Diane Lauren Reidy, Lawrence Fong, Emily K. Bergsland

Institutions: University of California, San Francisco, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4245135890

Cites:

Cited by: 24

Related to: 10